Barclays Raises Rating on Schott Pharma, Citing Turnaround in Packaging Demand
Barclays upgraded Schott Pharma to Overweight, saying the firm appears to be at a growth inflection after several years of earnings downgrades. The broker pointed to renegotiated contracts, improving polymer demand and expansion in ready-to-use and specialty vials as drivers of accelerating revenue and profit. Schott's shares jumped more than 4% in…